Optieum Biotechnologies Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Optieum Biotechnologies Inc. is a biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers.
Since scFv being the connection of immune cell and target antigen, it is considered to be the center of CAR-T/BiTE biology. Thus, the modulation of scFv creates a substantial butterfly effects to CAR-T/BiTEs anti-tumor effects. - modulation of scFvs increases longevity, proliferation, distribution etc -
Our proprietary platform technology, Eumbody System™, enables to develop and detect an scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.
We have recently entered into a collaboration with Daiichi Sankyo (Tokyo Stock Exchange: 4568) and currently seeking potential partners for CAR-T cell/BiTE development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
Platform Technology
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Optieum Biotechnologies Inc.